SEC Form 4 · accession 0001104659-19-004817
AGILE THERAPEUTICS INC · AGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Altomari
Officer — Chief Executive Officer · Director
Period of report
Jan 29, 2019
Accepted (ET)
Jan 31, 2019 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261249
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.84 | Jan 29, 2019 | A | 540,900 | A | — | Jan 28, 2029 | Common Stock | 540,900 | 540,900 | D |
| Employee Stock Option (Right to Buy)F1 | $2.50 | Jan 29, 2019 | A | 154,400 | A | — | Jan 28, 2029 | Common Stock | 154,400 | 154,400 | D |
Explanation of responses
- F1This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023.